Florian Fischer
Plus aucun poste en cours
Profil
Florian Fischer is the founder of MedVenture Partners GmbH, which was founded in 2002.
He held the position of Managing Director from 2002 to 2020.
Dr. Fischer also held former positions at AbCheck sro, Amphivena Therapeutics, Inc., Deutsche Bank AG, Affimed NV, KPMG LLP, Affimed NV Niederlassung Deutschland, Vivendy Therapeutics Ltd., and Vectura GmbH.
Dr. Fischer's education includes a doctorate from the University of Bielefeld and an undergraduate degree from Humboldt-Universität zu Berlin.
Anciens postes connus de Florian Fischer
| Sociétés | Poste | Fin |
|---|---|---|
MedVenture Partners GmbH
 MedVenture Partners GmbH Investment ManagersFinance MedVenture Partners GmbH engages in the provision of corporate finance and strategy advisory services. The firm focuses on life sciences and healthcare. It specializes in corporate finance, economic evaluation of health technologies, corporate strategy, as well as part-time and interim management. The company was founded by Florian Fischer on May 28, 2002 and is headquartered in Pullach, Germany. | Directeur Général | 03/02/2020 |
Affimed NV Niederlassung Deutschland
 Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Corporate Officer/Principal | 02/02/2020 |
| AFFIMED N.V. | Directeur Financier/CFO | 02/02/2020 |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | 01/01/2018 |
Vivendy Therapeutics Ltd.
 Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | Directeur Financier/CFO | 10/03/2014 |
Formation de Florian Fischer
| University of Bielefeld | Doctorate Degree |
| Humboldt-Universität zu Berlin | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DEUTSCHE BANK AG | Finance |
| AFFIMED N.V. | Health Technology |
| Entreprise privées | 7 |
|---|---|
AbCheck sro
 AbCheck sro Packaged SoftwareTechnology Services Part of Affimed NV, AbCheck sro is a Czech company that specializes in discovering and optimizing human therapeutic antibodies using advanced technology platforms. The company is based in Plzen, Czechia. The company offers personalized approaches to meet the specific needs of its customers and designs high-quality leads using both cutting-edge and classical technologies. AbCheck has proven its capabilities in multiple partnerships and is a wholly-owned subsidiary of Affimed GmbH. | Technology Services |
KPMG LLP
 KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Commercial Services |
Affimed NV Niederlassung Deutschland
Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Health Technology |
Vivendy Therapeutics Ltd.
Vivendy Therapeutics Ltd. Hospital/Nursing ManagementHealth Services Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland. | Health Services |
MedVenture Partners GmbH
MedVenture Partners GmbH Investment ManagersFinance MedVenture Partners GmbH engages in the provision of corporate finance and strategy advisory services. The firm focuses on life sciences and healthcare. It specializes in corporate finance, economic evaluation of health technologies, corporate strategy, as well as part-time and interim management. The company was founded by Florian Fischer on May 28, 2002 and is headquartered in Pullach, Germany. | Finance |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Retail Trade |
Vectura GmbH
 Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Health Technology |